Jackson Center, PA, September 28, 2020 – Children are far less susceptible than adults to the Coronavirus (1, 2). Halberd Corporation’s (OTC PINK: "HALB") scientists have determined the reason may be that adults have far more Angiotensin-Converting Enzyme 2 (ACE2) receptors in nasal membrane epithelial cells. ACE2 (3) is a membrane protein expressed in many ...
Jackson Center, PA, September 24, 2020 – Halberd Corporation (OTC PINK: "HALB") clarifies next steps in their unique research with Arizona State University. Halberd directed their research program to focus on that element of Covid-19 which makes the disease most contagious -- the spike antigen. ASU investigators have projected the production of the coronavirus spike ...
Jackson Center, PA, September 21, 2020 – Halberd Corporation (OTC PINK: "HALB") released a progress update on the research being conducted in conjunction with Arizona State University researchers. Dr. Qiang Chen, ASU’s lead researcher, reports the successful re-creation of the coronavirus spike protein disease antigen in laboratory research. With this breakthrough, Dr. Chen’s team will ...
Jackson Center, PA, September 17, 2020 – Halberd Corporation (OTC PINK: "HALB") today outlined the specifics of the second stage goals of the $1.4 Million seven-phase research project with Arizona State University. The second stage of the research involves an investigation of a method using dialysis, or a variant of dialysis, to remove the fluorescent ...
Jackson Center, PA, September 14, 2020 – Halberd Corporation (OTC PINK: "HALB") today released the specifics of the initial phase of the $1.4 Million seven-phase research project with Arizona State University. The University project for a rapid test to identify Covid-19 infection, from a sample such as saliva, mucus, blood and CSF will be based ...
Jackson Center, PA, September 8, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced Arizona State University (ASU) commenced its research work for Halberd Corp. The initial phases of ASU’s research focuses on the development of antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications for extracorporeal removal of ...
Jackson Center, PA, September 2, 2020 – Halberd Corporation (OTC PINK: "HALB") today revealed why they selected Arizona State University (ASU) to conduct sponsored research to develop a Covid-19 treatment. ASU is one of the fastest growing research universities in the country and ranks among the top 10 for Department of Health and Human Services ...
Jackson Center, PA, August 31, 2020 – Halberd Corporation (OTC PINK: "HALB") today announced the signing of a development agreement with Arizona State University (ASU) to conduct sponsored research to develop Halberd’s Covid-19 treatments. The work will focus on developing antibodies in support of Halberd’s two issued patents and three Covid-19 related provisional patent applications ...
Jackson Center, PA, August 27, 2020 – Halberd Corp. (OTC PINK: "HALB") is pleased to announce the successful completion of its search for a major research university partner. The University, to be announced, is engaged to develop compounds for use in Halberd’s patented extracorporeal treatment of Covid-19. Terms of the agreement have been finalized and ...
Jackson Center, PA, August 18, 2020 – Halberd Corp. (OTC PINK: "HALB") Chairman, President & CEO of Halberd Corporation, William A. Hartman, has received a number of questions from shareholders regarding the extracorporeal process for treatment of Covid-19. Below, Mr. Hartman responds to those questions. Q: There are various extracorporeal medical procedures being researched or ...